Biontech Se Sponsored Adr Stock News

Vaccine stocks could enjoy a longer Covid runway. Roughly six in 10 adults support Covid shots for children, according to the IBD/TIPP Poll.

BioNTech <> extended YTD decline with another intraday loss today after issuing its projection for COVID-19 vaccine sales for this year, the lower margin of which fell short of

BioNTech SE (NASDAQ: BNTX ) said its working with London-based AI developer InstaDeep to develop a new computational method that analyzes sequencing data and predicts high-risk variants SARS-CoV-2 . The early warning system combines structural modeling of the SARS-CoV-2 spike protein, and Full story available on Benzinga.com

BioNTech SE (BNTX) CEO Ugur Sahin on JPMorgan 40th Annual Healthcare Conference (Transcript)

BioNTech SE (NASDAQ: BNTX) said it's working with London-based AI developer InstaDeep to develop a new computational method that analyzes sequencing data and predicts high-risk variants SARS-CoV-2.

ANF, ARCO, BNTX, GSL, and KLIC have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2022.

Germany's BioNTech said on Tuesday it would likely generate up to 17 billion euros ($19 billion) in 2022 revenue from the COVID-19 vaccine it co-developed with partner Pfizer.

Shares of BioNTech SE BNTX, +8.57% were down 0.6% in premarket trading on Tuesday after the company said it developed a new system with InstaDeep Ltd. that uses a mix of modeling and artificial intell

Two developments contributed to the stock''s nice gain.

Two developments contributed to the stock's nice gain.

BioNTech <> and Crescendo Biologics have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and

Biotech stocks came under selling pressure along with the broader market, as rate hike fears seized Wall Street. The news flow, however, was scanty. Last week, the Food and Drug Administration expanded the emergency use authorization it accorded for the Pfizer, Inc. (NYSE: PFE )- BioNTech SE (NASDAQ: BNTX ) vaccine. The expanded approval allows the use of a single booster dose in individuals 12 through 15 years of age, a third primary series dose for certain immunocompromised children 5 through 11 years of age, and the shortening of time between completion of primary vaccination and a booster dose to at least five months. Clinical readouts resulted in contrasting stock moves. Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT ) ended the week up about 80% after its lead candidate LB-100 was found to increase the responsiveness of diverse cancers to immunotherapy. On the other hand, Aligos Therapeutics, Inc. (NASDAQ: Full story available on Benzinga.com

"I Do Not Want To Have A Vaccination": NHS Doctor Tells UK Health Secretary On Camera Authored by Lily Zhou via The Epoch Times (emphasis ours), An NHS doctor told Health Secretary Sajid Javid on Friday that hes not happy with the governments Covid-19 vaccination mandate for health workers that is due to take effect in April. Health Secretary Sajid Javid (R) talks to consultant Steve James during a visit to Kings College Hospital in London on Jan. 7, 2022. (Stefan Rousseau/PA) The vaccination mandate has already come into effect for care home staff, volunteers, and visitors from Nov. 11. Parliament approved the mandate for frontline NHS workers on Dec. 14. Steve James, a consultant anesthetist at the Kings College Hospital, told Javid that he doesnt believe the science for mandating the vaccines is strong enough and the government should at least consider the nuance that some doctors have had antibodies through previous exposure to the CCP (Chinese Communist Party) virusthe virus that causes COVID-19. Im not happy about that, James told the health secretary after he asked an intensive care unit (ICU) their thoughts about the new rule to require CCP virus vaccination for NHS staff.

Moderna CEO Scrambles To Sell More Boosters As Omicron Wave Shows Signs Of Waning While the rest of the world rejoices at the possibility that the omicron wave might actually bring about the end of the pandemic (while also being bullish for stocks, as we explored earlier in a post about some recent findings out of South Africa ), vaccine makers are already strategizing about how they will convince the world to keep buying boosters when the imminent threat posed by COVID has receded. Speaking at a conference hosted by - who else? - Goldman Sachs, Moderna CEO Stephane Bancel said another round of vaccine boosters will probably be needed this fall, even if immunity to the rapidly spreading omicron does become widespread, like the South African scientists have warned. Bancel added that even if omicron finally causes COVID to become endemic, there will still be a need for people to get their shots, since it''s not clear how long the current wave of immunity will hold. And there''s always uncertainty, since noboody can say for sure what future iterations of SARS-CoV-2 will be like. "Assuming omicron is an acceleration to the endemic phase, I still believe we''re going to need boosters in the fall of 22 and forward," Bancel said during his presentation.